In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 29_suppl ( 2020-10-10), p. 61-61
Abstract:
61 Background: Incidence, healthcare resource utilization (HRU), and management costs associated with CRS and NE were assessed among pts in the KarMMa trial (NCT03361748) treated with ide-cel, a BCMA-directed CAR T cell therapy for RRMM. Methods: HRU occurring from onset to resolution of CRS and/or NE and consistent with trial management guidelines were identified from the clinical trial database. Costs associated with CRS or NE by grade (Gr) were applied using public databases and literature on United States national average costs from the health system perspective and aggregated across duration of events. Results: Of 128 pts treated with ide-cel, 107 had CRS with or without NE including 84 (65.6%) with CRS only and 23 (18.0%) with both; no pts had NE only. All cases of CRS with NE occurred concurrently (≥1 d of overlap). Most pts with CRS and/or NE had Gr ≤2 events (96/107, 89.7%); none had both Gr ≥3 CRS and NE. Of the 23 pts with both, 22 (95.6%) had CRS before or on the same day as NE. Among the 15 pts who had CRS before NE, NE developed a median of 2 days after CRS onset. Of the 107 pts with CRS with or without NE, 67 (62.6%) received tocilizumab, 26 (24.3%) received both tocilizumab and corticosteroids, and 19 (17.8%) received intensive care. Only 5 pts (4.7%) required dialysis or intubation, all of whom had Gr ≥3 events. Management costs for CRS with or without NE were largely driven by hospitalizations (Table). Median costs ranges were $18,497-$23,285 for Gr ≤2 CRS, $33,183 for Gr ≤2 CRS with NE, and $60,588-$121,535 for Gr ≥3 CRS with or without NE. Overall median costs for Gr ≤2 vs Gr ≥3 CRS with or without NE were $21,693 vs $99,894. Conclusions: In KarMMa, CRS or NE events were primarily Gr ≤2. An increase in HRU and management costs were associated with more severe CRS or NE with a sharp increase in Gr ≤2 vs Gr ≥3. Clinical trial information: NCT03361748 . [Table: see text]
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2020.38.29_suppl.61
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2020
detail.hit.zdb_id:
2005181-5
Permalink